Subjective Experiences of Antipsychotic Treatment: A Comparison of First- and Second-generation Medications among Patients with Schizophrenia
Journal Title: International Neuropsychiatric Disease Journal - Year 2016, Vol 7, Issue 1
Abstract
Aims: The patient’s perspective of antipsychotic treatment has been a relatively neglected area of research. Whether subjective experiences of antipsychotic treatment are better among patients on second-generation antipsychotics (SGAs), than those on first-generation antipsychotics (FGAs) has also evoked some controversy. This study attempted a longitudinal comparison of attitudes toward treatment, subjective well-being and quality of life (QOL) between patients on SGAs and FGAs. Socio-demographic and clinical correlates of these subjective experiences were also examined. Methodology: Standardised ratings of insight, psychopathology, side-effects, attitudes, subjective well-being and QOL were carried out among 40 patients with schizophrenia on SGAs and 30 on FGAs, over a 6-month period. Results: Both groups were similar in the first 3-month period, apart from the slightly greater severity of illness in the FGA group. Differences in symptom-severity and side-effects emerged between the groups over the course of follow-up. Moreover, as the study progressed, differences also became apparent in subjective experiences; patients on SGAs had significantly better attitudes, subjective well-being and QOL than those on FGAs. However, differences between individual SGAs (olanzapine and risperidone) on these indices were minimal. The three indices of subjective experience were highly correlated with each other. Older age, being employed, greater insight, lower symptom-severity and the absence of side-effects demonstrated significant positive associations with different aspects of subjective experiences. Conclusions: Patients on SGAs had a more favourable profile of subjective experiences with treatment than those on FGAs. These differences seemed to be determined mainly by differences in symptom-severity and side-effects.
Authors and Affiliations
Subho Chakrabarti, Nisha Warikoo, Sandeep Grover
Keywords
Related Articles
- EP ID EP241847
- DOI 10.9734/INDJ/2016/24769
- Views 142
- Downloads 0
EEG Characterizations and Clinical Features in Sudanese Patients with Panayiotopoulos Syndrome
Introduction: Panayiotopoulos syndrome (PS) is an age-related, and a relatively frequent benign epileptic syndrome, characterised by predominantly autonomic symptoms and/or simple motor focal seizures followed, or not, b...
Cotard’s Syndrome: Clinical Case Presentation and Literature Review
In 1880 French neurologist Jules Cotard described a condition characterized by delusion of negation (nihilistic delusion) in a melancholia context. Recently, there has been a resurgence of interest in Cotard’s syndrome....
Conversion Disorder in the Elderly Population: Case Report
Conversion disorder is a psychological disorder that appears as a loss in individual’s motor and/or sensory functions without any apparent organic reason. It was reported that it is usually observed in 15 – 35 years old...
Evaluation of Oxidative Stress in Liver Cirrhosis Patients to Early Diagnosis of Minimal Hepatic Encephalopathy
Introduction: Minimal hepatic encephalopathy (MHE) is mildest form of the spectrum of neuropsychiatric and neurocognitive impairment in cirrhosis. Early recognition of this impairment may prevent the progression or may d...
Substance Use Disorder: Biological Mechanisms, Clinical Effects and Neuroadaptations
Substance use disorder is characterized by a psychological dependence on a substance or a drug that is beyond voluntary control and that can cause serious harm to the individual when used repetitively. The use of drugs,...